Abstract
Introduction
Ž . Semicarbazide-sensitive amine oxidase SSAO is a common name for a group of heterogeneous amine oxidases which are present in various mammalian tissues, especially in vascular smooth muscle cells, but also in w x cartilage, adipose tissue and plasma 1-4 . SSAO differs from the well-known monoamine oxidases MAO-A and MAO-B in co-factor and in substrate and inhibition pattern. The physiological role of SSAO is not clear, but may include protection against various endogenous and exoge-) Corresponding author. Tel. q31 10 4633764; Fax q31 10 4634531. nous monoamines. In recent years, however, several potentially deleterious effects of SSAO have come to light. The cardiovascular toxin allylamine induces myocardial necrosis and fibrosis; its toxicity has been found to be caused by conversion of allylamine by SSAO to highly cytotoxic w x acrolein 5 . The endogenous compounds methylamine and aminoacetone have been reported to be readily transformed by SSAO to the corresponding aldehydes formaldehyde and methylglyoxal, while at the same time generating hydrogen peroxide and ammonia. This may cause deleteri-Ž . ous effects in 3 ways: 1 direct cytotoxic damage to Time for primary review 28 days.
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Ž . PII S 0 0 0 8 -6 3 6 3 9 6 0 0 2 0 9 -X ( )endothelial cells by the aldehydes and hydrogen peroxide Ž . formed; 2 reaction of aldehydes with structural and functional proteins to form adducts and advanced glycation Ž . endproducts; and 3 increased radical formation and oxw x idative stress from the hydrogen peroxide generated 6-11 . An increasing body of evidence thus seems to indicate that SSAO may be involved in the pathogenesis of vascular endothelial damage.
Recently, we reported that plasma SSAO was elevated in patients with insulin-dependent diabetes mellitus, a conw x dition in which endothelial function is impaired 12 . Endothelial dysfunction may also be a prominent feature of Ž . w x congestive heart failure CHF 13 , but whether SSAO is also increased in this disorder is not known. In the present study we therefore investigated plasma SSAO levels in Ž patients with moderate to severe CHF NYHA class III-. Ž . IV . Plasma norepinephrine NE and atrial natriuretic Ž . peptide ANP , parameters considered to be relevant for assessment of CHF, were also measured and compared with SSAO activities.
Methods

Subjects
Blood was obtained from 271 patients with moderate to severe congestive heart failure who participated in a large w x multicenter study 14 . The samples of the present study were baseline values of patients who entered this study in Ž . the Netherlands. Most patients 95% were on ACE-inhibitor treatment. Characteristics of the patients are given in Ž . Table 1 . Left ventricular ejection fraction LVEF was measured by radionuclide ventriculography or echocardiography. At baseline an assessment of functional class was made, and patients were divided into NYHA III, III-IV, or IV. As the latter group comprised only 7 patients, these were combined with the 79 patients classified as III-IV to form one group henceforth called IIIrIV.
Seventy-seven participants of the Rotterdam Study were used as controls. The Rotterdam Study is a populationbased follow-up study of 7983 inhabitants aged 55 years or older living in the Rotterdam suburb of Ommoord. The design of the study has been described in detail elsewhere w x 15 . The 77 controls were randomly sampled from the group of Rotterdam Study participants younger than 71 years at time of baseline examination who were not receiving treatment for heart failure, and whose fractional short-Ž . ening calculated from M-mode echocardiography was higher than the 25th percentile. Patients with diabetes mellitus or previous myocardial infarction were excluded. LVEF in these controls was estimated using Quinones' prediction formula: LVEF s 1.7 = fractional shortening w x 16 .
The investigations conformed with the principles outlined in the Declaration of Helsinki.
Methods
For measurement of SSAO and norepinephrine, blood was collected in 10 ml heparinized tubes containing 12 mg Ž . of glutathione and centrifuged 48C, 15 min, 3000 = g . Blood for measurement of ANP was collected in tubes Ž containing EDTA and aprotinin 1.9 mg and 100 kIUrml . blood, respectively . Plasma was stored at y808C. Plasma norepinephrine was determined by high-performance liqw x uid chromatography with fluorometric detection 17 . Plasma ANP was determined with a commercially availw x able radioimmunoassay kit 18 .
Plasma SSAO activity was measured as reported previw x ously 19 . Briefly, plasma, after preincubation with clorgyline to inactivate any MAO possibly present, was incubated for 1 h with the SSAO-substrate benzylamine at 378C. The amount of benzaldehyde generated was quantified by HPLC with fluorometric detection after derivatiza-Ž . tion with dimedone 5,5-dimethyl-1,3-cyclohexanedione . SSAO activity was expressed as pmol of benzaldehyde formed per min per ml of plasma, or mUrl. The assay shows excellent linearity; inter-and intra-assay variabilities are both 7%. Plasma SSAO activity is stable when stored at y808C. No gender difference has been found in normal controls.
Statistics
For comparison between groups Student's t-test and the Pearson correlation coefficient were used in case of normally distributed variables, and Mann-Whitney's test and Spearman correlation coefficient in the case of skewed distribution variables. Univariate and stepwise multiple regression analyses were performed on the log-transformed ( )SSAO values, and evaluated by the F-test statistic. A P-value of -0.05 was considered statistically significant. SAS version 6.10 was used to perform the statistical analyses.
Results
In the 271 patients with CHF, plasma SSAO was Ž significantly higher than in the controls Table 1 and Fig. . 1A . When the patients were divided into two groups Ž according to NYHA class III and IIIrIV the combination . III-IV and IV , plasma SSAO was higher in the latter Ž group than in the group with NYHA class III Table 2 and . Fig. 1B ; both subgroups had higher plasma SSAO than Ž . controls P -0.001 . Fifty-eight of the CHF patients also had diabetes mellitus. When a subdivision was made according to the absence or presence of diabetes mellitus in the CHF patients, those with diabetes mellitus had significantly higher plasma SSAO levels than those without Ž . Table 2 and Fig. 1C . Plasma SSAO levels in the CHF patients without concomitant diabetes mellitus, however, Ž were still significantly higher than in the controls P s . 0.0046 . Patients with diabetes mellitus had baseline characteristics similar to patients without diabetes mellitus, Ž except for a slightly higher systolic blood pressure Table  . 2 . Plasma NE and plasma ANP were higher in NYHA Ž group IIIrIV than in NYHA class III P -0.0001, Table  . 2 . There was no difference in plasma NE or in plasma ANP between the groups with and without concomitant diabetes mellitus. Ž . Linear regression analysis Fig. 2 showed significant Ž correlations of plasma SSAO with plasma ANP r s 0.42;
. Ž P -0.0001 and weaker correlations with plasma NE r s . Ž 0.27; P -0.0001 and with LVEF r sy0.13; P s . 0.0162 .
In a univariate analysis SSAO activity in the CHF Ž patients taken as the logarithm because of skewed distri-Ž . Ž . Ž . Fig. 1 . Plasma SSAO activities meanqSD in: A controls CONT and Ž . Ž . patients with congestive heart failure CHF ; B patients with NYHA Ž . Ž . class III and NYHA class IIIrIV; C patients without yDM and with Ž . q DM concomitant diabetes mellitus. . bution was found to correlate amongst others with plasma ANP and NE, group, diabetes, angina pectoris, heart rate, weight, LVEF, cardiothoracic ratio and frusemide dose. No ) P s 0.02 vs. no DM. ) ) P -0.01 vs. no DM.
( )correlation was found with sex, age, blood pressure, etiology of CHF and dose of ACE-inhibitor. All parameters with P -0.1 in the univariate analysis were used in a Ž . stepwise multiple regression analysis of log SSAO activity as the dependent variable in a general linear model procedure. The most important parameters for predicting Ž . SSAO activity were plasma ANP F s 21.76, P -0.0001 , Ž . plasma NE F s 10.45, P s 0.0014 , cardiothoracic ratio Ž . Ž F s 10.44, P s 0.0014 , the presence of DM F s 19.30, . Ž P -0.0001 and the presence of angina pectoris F s . 16.72, P -0.0001 . The latter is negatively correlated to SSAO activity. The over-all model had an F-value of Ž . 22.02 P -0.0001 with a correlation coefficient of 0.55.
Discussion
The major finding of the present study is that plasma SSAO is elevated in patients with CHF compared to controls. Age, sex and medication used were not found to be determinants of SSAO activity. The effect of small differences in mean age and sex distribution between the CHF and the control groups therefore appears to be negligible. The higher SSAO activities in CHF are not likely to be due to possibly decreased renal function in the CHF patients, since plasma SSAO activities in 12 patients with Ž chronic renal failure serum creatinine 1090 " 411 . Ž . mmolrl were found to be not elevated 327 " 127 mUrl .
Plasma SSAO activity appears to increase with severity Ž . of the disease Fig. 1B . This is confirmed by the results of the multivariate analysis, which shows that the most important variables for plasma SSAO activity are plasma ANP and NE, as well as cardiothoracic ratio, all parameters known to increase with increasing severity of CHF. The plasma SSAO activity in CHF is somewhat higher Ž than in patients with uncomplicated diabetes mellitus 589 . vs. 486 mUrl , but similar to the activity in patients with diabetes mellitus with retinopathy andror nephropathy Ž .w x 581-646 mUrl 12 . It is noteworthy that patients with both CHF and diabetes mellitus have even higher plasma SSAO activities.
It has been suggested that previous reports on serum MAO activities may in fact have been measurements of w x SSAO 6,12 . In this respect, it should be noted that w x w x McEwen and Harrison 20 , as well as Nilsson et al. 21 reported increased serum MAO activities in respectively 79 and 41 patients with heart failure, correlating with the severity of the disease. Matsumoto et al., however, found no significantly increased serum MAO in 6 patients with w x chronic heart failure compared to controls 22 .
The origin of elevated plasma SSAO is not known. Recently the biochemical properties of circulating serum SSAO were found to be identical to those of the SSAO w x from vascular tissues 23 . It might be hypothesized that increased leakage of SSAO from the membranes of proliferating smooth muscle cells, after vascular endothelial damage, may be the cause of the elevated plasma SSAO levels. Alternatively, the increase may be in response to increased levels of SSAO substrates. Transformation of endogenous amines like methylamine and aminoacetone into aldehydes, ammonia and hydrogen peroxide may lead Ž . to further vascular endothelial damage. Whether plasma levels of methylamine andror aminoacetone are increased w x in CHF, as has been suggested for diabetes mellitus 24,25 , has not been investigated. It is of interest to note that methylamine is, amongst others, formed by metabolism of the stress hormone adrenaline, and is a component of cigarette smoke. Both stress and smoking are associated with increased risk for cardiovascular complications.
Apart from cytotoxic damage to the endothelium, aldehydes may also be deleterious due to reaction to and modification of proteins. Methylglyoxal, for example, has been suggested to be involved in the development of diabetic complications, and the methylglyoxal scavenger, aminoguanidine, is presently under investigation as a prow x phylactic agent for prevention of such complications 11 . Whether methylglyoxal mainly stems from oxidation by SSAO of aminoacetone, or from enzymatic and non-enzymatic elimination of phosphate from dihydroxyacetone phosphate and glyceraldehyde 3-phosphate, remains to be w x established 26 . In the former case, andror if formation of formaldehyde from methylamine is substantial, treatment Ž . with an SSAO inhibitor e.g., hydralazine may prove useful in preventing vascular damage, not only in diabetes mellitus, but possibly also in CHF.
The correlation of plasma SSAO with plasma NE and ANP, which are often regarded as good indicators for w x severity and prognosis of CHF 27,28 , raises the possibility that plasma SSAO may likewise be an indicator. Measurements in long-term survival studies will have to be performed, however, to further establish the potential of plasma SSAO as an indicator for severity and prognosis of CHF. Also, in view of the elevated SSAO in diabetes mellitus, SSAO may turn out to be more generally an indicator for endothelial dysfunction than specifically for severity of CHF.
We conclude that plasma SSAO is increased in CHF, as it is in diabetes mellitus; the elevation is greater with increasing severity of the disease. The possibility that SSAO not only increases after vascular endothelial damage, but may even play a role in the development of vascular endothelial damage, raises interesting questions with regard to diagnosis, follow-up, prognosis and even preventive therapy. 
